01UK / EU
United Kingdom & Europe
Origin, partnerships and regulated portfolio development
Manufacturer engagement, UK/EU sourcing and structured export opportunities for differentiated healthcare portfolios.
Explore opportunity fitMarkets & global reach
International ambition. Country-level execution discipline.
ORBIWAY develops selected healthcare corridors by matching credible supply with demand, regulatory feasibility and qualified local execution.
Discuss a target marketPriority corridors
A network model designed around market realities.
The regions below represent priority engagement corridors, not a claim of a permanent office, licence or distribution authorisation in every country. Local status is confirmed for each mandate.
Supply-side partnerships Market-access pathways Institutional demand
02GCC
GCC
Institutional procurement and market access
Saudi Arabia, UAE, Oman, Qatar, Kuwait and Bahrain, with engagement shaped around local regulatory and tender conditions.
Explore opportunity fit03LEV
Levant & Iraq
Registration, supply and representation
Jordan, Lebanon, Iraq and adjacent markets, supported through qualified local relationships and requirement-specific planning.
Explore opportunity fit04NAF
North Africa
Portfolio expansion and public procurement
Egypt, Libya, Morocco, Algeria and Tunisia, with country-level screening before any commercial or regulatory commitment.
Explore opportunity fit05SSA
Sub-Saharan Africa
Access programmes and institutional supply
Selected East, West and Southern African opportunities where documentation, affordability and execution capacity align.
Explore opportunity fit06GLOBAL
Strategic global sourcing
Qualified supply-side network
Engagement with manufacturers and authorised supply channels in recognised regulatory jurisdictions and proven production markets.
Explore opportunity fitMarket-entry decision frame
Five questions before committing capital or exclusivity.
- 01
Is the product regulatorily viable?
Classification, registration route, dossier status, reference-market evidence and local rules.
- 02
Is the commercial model bankable?
Price corridors, reimbursement, tender dynamics, volumes, margin stack and working capital.
- 03
Is the local partner fit for purpose?
Licence scope, category strength, tender access, pharmacovigilance and execution capacity.
- 04
Can supply withstand market demand?
MOQ, capacity, lead time, shelf life, pack adaptation, serialization and logistics conditions.
- 05
Are governance and incentives aligned?
Territory, exclusivity, milestones, forecasts, performance rights and decision cadence.
Start a focused conversation
Evaluate a market before making a market-entry commitment.
Share the product, current registrations, available dossier, target geography and preferred model for an initial opportunity assessment.